피복 스텐트 시장 규모, 점유율 및 동향 분석 보고서 : 디바이스 유형별, 해부학적 부위별, 지역별 및 부문별 예측(2026-2033년)

Covered Stent Market Summary

The global covered stent market size was estimated at USD 1.4 billion in 2025 and is projected to reach USD 2.1 billion by 2033, growing at a CAGR of 4.6% from 2026 to 2033. The growth is driven by the increasing prevalence of peripheral artery disease and complex aortoiliac occlusive conditions, rising volumes of endovascular procedures, and expanding preference for minimally invasive revascularization.

Advancements in covered stent design, including enhanced deliverability, radial strength, and long-term patency performance, continue to support broader clinical adoption. The key drivers of the market are the rising prevalence of peripheral artery and aortoiliac occlusive diseases, technological advancements in covered stent design and materials, increasing adoption of minimally invasive endovascular procedures and increasing adaptation of minimally invasive endovascular procedures.

Global Covered Stent Market Report Segmentation

This report forecasts volume & revenue growth at the global, regional, and country levels,and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global covered stent market report based on device type, anatomy, and region:

Total Addressable Market (TAM)

• Anatomy Outlook (Unit Volume and Procedure Volume in Thousand Units; Revenue, USD Million, 2021 - 2033)
• Iliac
  • Common Iliac
  • External Iliac
• AIOD (Aortoiliac Occlusive Disease)
• SFA (Superficial Femoral Artery)
• Complex EVAR
• FEVAR
• BEVAR
• Renal Vessel

Serviceable Obtainable Market (SOM)

• Device Type Outlook (Unit Volume and Procedure Volume in Thousand Units; Revenue, USD Million, 2021 - 2033)
• Balloon Expandable
  • Iliac
  • Common Iliac
  • External Iliac
  • AIOD (Aortoiliac Occlusive Disease)
  • Complex EVAR
  • FEVAR
  • BEVAR
  • Renal Vessel AIOD (Aortoiliac Occlusive Disease)
• Self-expanding Covered Stent (SX-CS)
  • External Iliac
  • SFA (Superficial Femoral Artery)
  • Complex EVAR
  • FEVAR
  • BEVAR
• Anatomy Outlook (Unit Volume and Procedure Volume in Thousand Units; Revenue, USD Million, 2021 - 2033)
• Iliac
  • Common Iliac
  • External Iliac
• AIOD (Aortoiliac Occlusive Disease)
• SFA (Superficial Femoral Artery)
• Complex EVAR
• FEVAR
• BEVAR
• Renal Vessel
• Regional Outlook at both TAM and SOM (Unit Volume and Procedure Volume in Thousand Units; Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment scope
  • 1.1.2. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation and Validation
• 1.6. Model Details
• 1.7. Research Assumptions
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Device type outlook
  • 2.2.2. Anatomy outlook
• 2.3. Competitive Insights

Chapter 3. Global Covered Stent Market Variables, Trends and Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Global Ejection Fraction: Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  • 3.3.2. PESTLE Analysis
• 3.4. Pricing Analysis
  • 3.4.1. Average Selling Price (ASP) by Device Type
  • 3.4.2. Average Selling Price (ASP) by Region
  • 3.4.3. Estimated Average Selling Price (ASP) Device X Anatomy, 2024 (USD)
• 3.5. Development, Regulatory & Partnership Pathways for Complex EVAR (FEVAR / BEVAR)
  • 3.5.1. Clinical Evidence Requirements
    • 3.5.1.1. Typical evidence expectations by region
    • 3.5.1.2. Study design and endpoint considerations
    • 3.5.1.3. Study design and endpoint considerations
    • 3.5.1.4. Role of registries and real-world evidence
  • 3.5.2. Regulatory Pathways & Implications, U.S. and Europe
    • 3.5.2.1. Applicable approval pathways
    • 3.5.2.2. Timelines and complexity drivers
    • 3.5.2.3. Strategic implications
  • 3.5.3. Financial implications of different development pathways
    • 3.5.3.1. Key development and validation cost drivers for complex EVAR, FEVAR, BEVAR devices
    • 3.5.3.2. Clinical and regulatory investment considerations
    • 3.5.3.3. Trade-offs between pathways
    • 3.5.3.4. Post-approval cost implications
  • 3.5.4. Partnership & Collaboration Models
    • 3.5.4.1. Prevalence of partnerships with AAA platform manufacturers
    • 3.5.4.2. Common collaboration structures (codevelopment, licensing, distribution)
    • 3.5.4.3. Strategic rationale and adoption impact
    • 3.5.4.4. Advantages and limitations of partnership approaches
  • 3.5.5. Bridging Stent Strategy Approaches
    • 3.5.5.1. Platform-specific vs platform-agnostic design strategies
    • 3.5.5.2. Adoption and compatibility drivers
    • 3.5.5.3. Commercial positioning approaches
    • 3.5.5.4. Strategic implications for market entry and scalability
• 3.6. Clarification on inclusion of Specific Components
• 3.7. Vessel-Level Renal Artery Split for FEVAR/BEVAR Bridging Stent Usage
• 3.8. Average Device Utilization per Case

Chapter 4. Global Total Addressable Market (TAM) Covered Stent Market Segment Analysis, By Anatomy, 2021-2033 (USD Million, Unit Volume and Procedure Volume in Thousand Units)

• 4.1. Definition and Scope
• 4.2. Anatomy Market Share Analysis, 2025 and 2033
• 4.3. Segment Dashboard
• 4.4. Global Covered Stent Market, By Anatomy, 2021 to 2033
  • 4.4.1. Iliac
    • 4.4.1.1. Iliac Market Estimates and Forecasts 2021 To 2033 (USD Million)
      • 4.4.1.1.1. Common Iliac
        • 4.4.1.1.1.1. Common Iliac Market Estimates and Forecasts 2021 To 2033 (USD Million)
      • 4.4.1.1.2. External Iliac
        • 4.4.1.1.2.1. External Iliac Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 4.4.2. AIOD (Aortoiliac Occlusive Disease)
    • 4.4.2.1. AIOD (Aortoiliac Occlusive Disease) Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 4.4.3. SFA (Superficial Femoral Artery)
    • 4.4.3.1. SFA (Superficial Femoral Artery) Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 4.4.4. Complex EVAR
    • 4.4.4.1. Complex EVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 4.4.5. FEVAR
    • 4.4.5.1. FEVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 4.4.6. BEVAR
    • 4.4.6.1. BEVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
  • 4.4.7. Renal Vessel
    • 4.4.7.1. Renal Vessel Market Estimates and Forecasts 2021 To 2033 (USD Million)

Chapter 5. Global Serviceable Obtainable Market (SOM) Covered Stent Market Segment Analysis, By Device Type, 2021-2033 (USD Million, Unit Volume and Procedure Volume in Thousand Units)

• 5.1. Definition and Scope
• 5.2. Device Type Market Share Analysis, 2025 and 2033
• 5.3. Segment Dashboard
• 5.4. Global Covered Stent Market, By Device Type, 2021 to 2033
  • 5.4.1. Balloon Expandable
    • 5.4.1.1. Balloon Expandable Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 5.4.1.2. Balloon Expandable Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
      • 5.4.1.2.1. Iliac
        • 5.4.1.2.1.1. Iliac Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 5.4.1.2.1.2. Iliac Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
          • 5.4.1.2.1.2.1. Common Iliac
            • 5.4.1.2.1.2.1.1. Common Iliac Market Estimates and Forecasts 2021 To 2033 (USD Million)
            • 5.4.1.2.1.2.1.2. Common Iliac Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
          • 5.4.1.2.1.2.2. External Iliac
            • 5.4.1.2.1.2.2.1. External Iliac Market Estimates and Forecasts 2021 To 2033 (USD Million)
            • 5.4.1.2.1.2.2.2. External Iliac Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
      • 5.4.1.2.2. AIOD (Aortoiliac Occlusive Disease)
        • 5.4.1.2.2.1. AIOD (Aortoiliac Occlusive Disease) Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 5.4.1.2.2.2. AIOD (Aortoiliac Occlusive Disease) Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
      • 5.4.1.2.3. Complex EVAR
        • 5.4.1.2.3.1. Complex EVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 5.4.1.2.3.2. Complex EVAR Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
      • 5.4.1.2.4. FEVAR
        • 5.4.1.2.4.1. FEVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 5.4.1.2.4.2. FEVAR Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
      • 5.4.1.2.5. BEVAR
        • 5.4.1.2.5.1. BEVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 5.4.1.2.5.2. BEVAR Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
      • 5.4.1.2.6. Renal Vessel AIOD (Aortoiliac Occlusive Disease)
        • 5.4.1.2.6.1. Renal Vessel AIOD (Aortoiliac Occlusive Disease) Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 5.4.1.2.6.2. Renal Vessel AIOD (Aortoiliac Occlusive Disease) Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 5.4.2. Self-expanding Covered Stent (SX-CS)
    • 5.4.2.1. Self-expanding Covered Stent (SX-CS) Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 5.4.2.2. Self-expanding Covered Stent (SX-CS) Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
      • 5.4.2.2.1. External Iliac
        • 5.4.2.2.1.1. External Iliac Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 5.4.2.2.1.2. External Iliac Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
      • 5.4.2.2.2. SFA (Superficial Femoral Artery)
        • 5.4.2.2.2.1. SFA (Superficial Femoral Artery) Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 5.4.2.2.2.2. SFA (Superficial Femoral Artery) Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
      • 5.4.2.2.3. Complex EVAR
        • 5.4.2.2.3.1. Complex EVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 5.4.2.2.3.2. Complex EVAR Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
      • 5.4.2.2.4. FEVAR
        • 5.4.2.2.4.1. FEVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 5.4.2.2.4.2. FEVAR Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)
      • 5.4.2.2.5. BEVAR
        • 5.4.2.2.5.1. BEVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 5.4.2.2.5.2. BEVAR Market Estimates and Forecasts 2021 To 2033 (Unit Volume and Procedure Volume, In Thousand Units)

Chapter 6. Global Serviceable Obtainable Market (SOM) Covered Stent Market Segment Analysis, By Anatomy, 2021-2033 (USD Million, Unit Volume and Procedure Volume in Thousand Units)

• 6.1. Definition and Scope
• 6.2. Anatomy Market Share Analysis, 2025 and 2033
• 6.3. Segment Dashboard
• 6.4. Global Covered Stent Market, By Anatomy, 2021 to 2033
  • 6.4.1. Iliac
    • 6.4.1.1. Iliac Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 6.4.1.2. Iliac Market Estimates and Forecasts 2021 To 2033 (Procedure Volume, In Thousand Units)
      • 6.4.1.2.1. Common Iliac
        • 6.4.1.2.1.1. Common Iliac Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 6.4.1.2.1.2. Common Iliac Market Estimates and Forecasts 2021 To 2033 (Procedure Volume, In Thousand Units)
      • 6.4.1.2.2. External Iliac
        • 6.4.1.2.2.1. External Iliac Market Estimates and Forecasts 2021 To 2033 (USD Million)
        • 6.4.1.2.2.2. External Iliac Market Estimates and Forecasts 2021 To 2033 (Procedure Volume, In Thousand Units)
  • 6.4.2. AIOD (Aortoiliac Occlusive Disease)
    • 6.4.2.1. AIOD (Aortoiliac Occlusive Disease) Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 6.4.2.2. AIOD (Aortoiliac Occlusive Disease) Market Estimates and Forecasts 2021 To 2033 (Procedure Volume, In Thousand Units)
  • 6.4.3. SFA (Superficial Femoral Artery)
    • 6.4.3.1. SFA (Superficial Femoral Artery) Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 6.4.3.2. SFA (Superficial Femoral Artery) Market Estimates and Forecasts 2021 To 2033 (Procedure Volume, In Thousand Units)
  • 6.4.4. Complex EVAR
    • 6.4.4.1. Complex EVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 6.4.4.2. Complex EVAR Market Estimates and Forecasts 2021 To 2033 (Procedure Volume, In Thousand Units)
  • 6.4.5. FEVAR
    • 6.4.5.1. FEVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 6.4.5.2. FEVAR Market Estimates and Forecasts 2021 To 2033 (Procedure Volume, In Thousand Units)
  • 6.4.6. BEVAR
    • 6.4.6.1. BEVAR Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 6.4.6.2. BEVAR Market Estimates and Forecasts 2021 To 2033 (Procedure Volume, In Thousand Units)
  • 6.4.7. Renal Vessel
    • 6.4.7.1. Renal Vessel Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 6.4.7.2. Renal Vessel Market Estimates and Forecasts 2021 To 2033 (Procedure Volume, In Thousand Units)

Chapter 7. Covered Stent Market Segment Analysis (TAM and SOM), By Region, 2021- 2033 (USD Million)

• 7.1. Regional Market Share Analysis, 2025 And 2033
• 7.2. Regional Market Dashboard
• 7.3. Regional Market Snapshot
• 7.4. Covered Stent Market Share by Region, 2025 And 2033:
• 7.5. North America
  • 7.5.1. North America Covered Stent Market, 2021 - 2033 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Scenario
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. U.S. Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.5.2.5. U.S. Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Scenario
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Canada Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.5.3.5. Canada Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Scenario
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Mexico covered stent market, 2021 - 2033 (USD Million)
    • 7.5.4.5. Mexico Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
• 7.6. Europe
  • 7.6.1. Europe Covered Stent Market, 2021 - 2033 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Scenario
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. UK Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.6.2.5. UK Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Scenario
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Germany Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.6.3.5. Germany Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Scenario
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. France Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.6.4.5. France Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Scenario
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Italy Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.6.5.5. Italy Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Scenario
    • 7.6.6.3. Competitive Scenario
    • 7.6.6.4. Spain Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.6.6.5. Spain Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.6.7. Norway
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Scenario
    • 7.6.7.3. Competitive Scenario
    • 7.6.7.4. Norway Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.6.7.5. Norway Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Regulatory Scenario
    • 7.6.8.3. Competitive Scenario
    • 7.6.8.4. Sweden Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.6.8.5. Sweden Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.6.9. Denmark
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Regulatory Scenario
    • 7.6.9.3. Competitive Scenario
    • 7.6.9.4. Denmark Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.6.9.5. Denmark Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Regulatory Scenario
    • 7.7.1.3. Competitive Scenario
    • 7.7.1.4. Japan Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.7.1.5. Japan Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.7.2. China
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Scenario
    • 7.7.2.3. Competitive Scenario
    • 7.7.2.4. China Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.7.2.5. China Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.7.3. India
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Scenario
    • 7.7.3.3. Competitive Scenario
    • 7.7.3.4. India Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.7.3.5. India Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.7.4. Australia
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Regulatory Scenario
    • 7.7.4.3. Competitive Scenario
    • 7.7.4.4. Australia Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.7.4.5. Australia Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Regulatory Scenario
    • 7.7.5.3. Competitive Scenario
    • 7.7.5.4. South Korea Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.7.5.5. South Korea Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.7.6. Thailand
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Regulatory Scenario
    • 7.7.6.3. Competitive Scenario
    • 7.7.6.4. Thailand Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.7.6.5. Thailand Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key Country Dynamics
    • 7.8.1.2. Regulatory Scenario
    • 7.8.1.3. Competitive Scenario
    • 7.8.1.4. Brazil Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.8.1.5. Brazil Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.8.2. Argentina
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Scenario
    • 7.8.2.3. Competitive Scenario
    • 7.8.2.4. Argentina Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.8.2.5. Argentina Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key Country Dynamics
    • 7.9.1.2. Regulatory Scenario
    • 7.9.1.3. Competitive Scenario
    • 7.9.1.4. South Africa Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.9.1.5. South Africa Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Regulatory Scenario
    • 7.9.2.3. Competitive Scenario
    • 7.9.2.4. Saudi Arabia Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.9.2.5. Saudi Arabia Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.9.3. UAE
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Regulatory Scenario
    • 7.9.3.3. Competitive Scenario
    • 7.9.3.4. UAE Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.9.3.5. UAE Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Regulatory Scenario
    • 7.9.4.3. Competitive Scenario
    • 7.9.4.4. Kuwait Covered Stent Market, 2021 - 2033 (USD Million)
    • 7.9.4.5. Kuwait Covered Stent Market, 2021 - 2033 (Unit Volume and Procedure Volume, In Thousand Units)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments and Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Estimated Company Market Share Analysis, By Anatomy, By Region, 2024/2025 (%)
  • 8.3.1. Estimated company market share analysis by Common Iliac, by Region 2024/2025 (%)
  • 8.3.2. Estimated company market share analysis by external Iliac, by Region 2024/2025 (%)
  • 8.3.3. Estimated company market share analysis by AIOD, by Region 2024/2025 (%)
  • 8.3.4. Estimated company market share analysis by SFA (Superficial Femoral Artery), by Region 2024/2025 (%)
  • 8.3.5. Estimated company market share analysis by Complex EVAR, by Region 2024/2025 (%)
  • 8.3.6. Estimated company market share analysis by FEVAR, by Region 2024/2025 (%)
  • 8.3.7. Estimated company market share analysis by BEVAR, by Region 2024/2025 (%)
  • 8.3.8. Estimated company market share analysis by Renal vessel, by Region 2024/2025 (%)
• 8.4. List of Other Emerging and Regional Manufacturers
• 8.5. Company Profiles (Balloon-Expandable Covered Stent)
  • 8.5.1. BD
    • 8.5.1.1. Company Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Cook
    • 8.5.2.1. Company Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Bentley InnoMed GmbH
    • 8.5.3.1. Company Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Medtronic
    • 8.5.4.1. Company Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Getinge AB
    • 8.5.5.1. Company Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. iVascular
    • 8.5.6.1. Company Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. W. L. Gore & Associates, Inc.
    • 8.5.7.1. Company Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
• 8.6. Company Profiles (Self-Expanding Covered Stent)
  • 8.6.1. W. L. Gore & Associates, Inc.
    • 8.6.1.1. Company Overview
    • 8.6.1.2. Financial Performance
    • 8.6.1.3. Product Benchmarking
    • 8.6.1.4. Strategic Initiatives
  • 8.6.2. Solaris Endovascular
    • 8.6.2.1. Company Overview
    • 8.6.2.2. Financial Performance
    • 8.6.2.3. Product Benchmarking
    • 8.6.2.4. Strategic Initiatives
  • 8.6.3. BD (Angiomed GmbH & Co. Medizintechnik KG)
    • 8.6.3.1. Company Overview
    • 8.6.3.2. Financial Performance
    • 8.6.3.3. Product Benchmarking
    • 8.6.3.4. Strategic Initiatives
  • 8.6.4. LeMaitre Vascular, Inc.
    • 8.6.4.1. Company Overview
    • 8.6.4.2. Financial Performance
    • 8.6.4.3. Product Benchmarking
    • 8.6.4.4. Strategic Initiatives
  • 8.6.5. Endologix LLC
    • 8.6.5.1. Company Overview
    • 8.6.5.2. Financial Performance
    • 8.6.5.3. Product Benchmarking
    • 8.6.5.4. Strategic Initiatives
  • 8.6.6. Artivion, Inc
    • 8.6.6.1. Company Overview
    • 8.6.6.2. Financial Performance
    • 8.6.6.3. Product Benchmarking
    • 8.6.6.4. Strategic Initiatives
  • 8.6.7. Merit Medical Systems
    • 8.6.7.1. Company Overview
    • 8.6.7.2. Financial Performance
    • 8.6.7.3. Product Benchmarking
    • 8.6.7.4. Strategic Initiatives